Medicare Enrolled
Dr. Sharad Jain, MD
Hematology & Oncology · Denton, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Jain from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jain? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Jain
Dr. Sharad Jain is a hematology & oncology in Denton, TX, with 19 years in practice. Based on federal Medicare data, Dr. Jain performed 83,167 Medicare services across 4,263 unique beneficiaries.
Between the years covered by Open Payments, Dr. Jain received a total of $27,466 from 36 pharmaceutical and/or device companies across 135 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Jain is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 11% volume in TX$ $27,466 industry payments
Medicare Practice Summary
Medicare Utilization ↗83,167
Medicare services
Top 11% in TX for hematology & oncology
4,263
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,377 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 24,990 | $0 | $5 |
| Iron sucrose injection (Venofer) | 16,200 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 10,655 | $2 | $20 |
| Contrast dye for imaging (iodine-based) | 10,263 | $0 | $3 |
| Pembrolizumab injection (Keytruda) | 4,800 | $43 | $137 |
| Denosumab injection (Prolia/Xgeva) | 2,760 | $18 | $66 |
| Dexamethasone injection (steroid) | 1,335 | $0 | $1 |
| Blood draw (venipuncture) | 1,321 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,169 | $8 | $36 |
| Comprehensive metabolic blood panel | 963 | $10 | $64 |
| Office visit, established patient (30-39 min) | 885 | $88 | $368 |
| Injection, granisetron hydrochloride, 100 mcg | 830 | $0 | $24 |
| Lactate dehydrogenase (enzyme) level | 742 | $6 | $31 |
| Anti-nausea injection (Aloxi/palonosetron) | 580 | $1 | $114 |
| Injection of additional new drug or substance into vein | 363 | $11 | $108 |
| Ferritin level test (iron stores) | 338 | $13 | $60 |
| Iron level test | 338 | $6 | $27 |
| Iron binding capacity test | 338 | $9 | $35 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 300 | $94 | $1,348 |
| Administration of chemotherapy into vein, 1 hour or less | 295 | $96 | $707 |
| Injection, leucovorin calcium, per 50 mg | 221 | $3 | $25 |
| Drug injection, under skin or into muscle | 204 | $10 | $96 |
| Injection, carboplatin, 50 mg | 203 | $2 | $300 |
| Injection, magnesium sulfate, per 500 mg | 180 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 162 | $22 | $157 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 159 | $47 | $313 |
| Injection, fluorouracil, 500 mg | 147 | $2 | $13 |
| Basic metabolic blood panel | 129 | $8 | $49 |
| Complete blood count (CBC), automated | 129 | $6 | $34 |
| Injection, zoledronic acid, 1 mg | 129 | $6 | $431 |
| Microscopic examination for white blood cells with manual cell count | 128 | $4 | $22 |
| Injection, diphenhydramine hcl, up to 50 mg | 112 | $1 | $7 |
| Ct scan of chest with contrast | 111 | $52 | $821 |
| Uric acid level test | 105 | $4 | $25 |
| Reticulated (young) platelet measurement | 105 | $35 | $143 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 95 | $54 | $211 |
| CT scan of abdomen and pelvis with contrast | 90 | $162 | $1,067 |
| Administration of chemotherapy into vein, each additional hour | 87 | $21 | $161 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 81 | $24 | $145 |
| Office visit, established patient, complex (40-54 min) | 74 | $132 | $496 |
| Administration of additional new drug or substance into vein, 1 hour or less | 73 | $49 | $344 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 73 | $93 | $657 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 71 | $15 | $100 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 63 | $1,095 | $4,802 |
| Hospital follow-up visit, moderate complexity | 61 | $61 | $247 |
| CT scan of chest, without contrast | 56 | $44 | $686 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 55 | $140 | $3,675 |
| Injection of drug or substance into vein | 53 | $27 | $247 |
| Irrigation of implanted venous access drug delivery device | 52 | $17 | $114 |
| Infusion, normal saline solution , 1000 cc | 51 | $2 | $19 |
| New patient office visit (45-59 min) | 47 | $112 | $565 |
| Ct scan of abdomen and pelvis without contrast | 40 | $74 | $560 |
| Red blood count automated, with additional calculations | 35 | $5 | $26 |
| Blood creatinine level | 33 | $5 | $31 |
| Urea nitrogen level to assess kidney function, quantitative | 33 | $4 | $24 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 31 | $346 | $1,722 |
| Application of on-body injector for under skin injection | 25 | $14 | $96 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 25 | $1 | $17 |
| Administration of additional new drug or substance into vein using push technique | 24 | $42 | $289 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 23 | $1 | $19 |
| Infusion into a vein for hydration, each additional hour | 22 | $10 | $75 |
| Flu vaccine, quadrivalent | 19 | $76 | $171 |
| Flu vaccine administration | 19 | $30 | $58 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 19 | $272 | $2,762 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $23 | $256 |
| Manual urinalysis test with examination using microscope, non-automated | 17 | $4 | $26 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 13 | $124 | $500 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.7% high complexity
60.5% medium
8.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$27,466
Total received (2018-2024)
Avg $3,924/year across 7 years
Top 17% in TX for hematology & oncology
36
Companies
135
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$21,628 (78.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,219 (11.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,807 (6.6%)
Other
Charitable contributions, space rental, and other categories
$812 (3.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$4,175
2023$10,899
2022$7,584
2021$3,464
2020$148
2019$724
2018$472
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Kite Pharma, Inc.
$11,810
AstraZeneca Pharmaceuticals LP
$4,236
Gilead Sciences, Inc.
$3,032
BeiGene USA, Inc.
$2,550
PharmaEssentia USA Corporation
$1,147
Novartis Pharmaceuticals Corporation
$901
Daiichi Sankyo Inc.
$707
PFIZER INC.
$560
E.R. Squibb & Sons, L.L.C.
$355
PUMA BIOTECHNOLOGY, INC.
$238
Incyte Corporation
$144
Merck Sharp & Dohme Corporation
$143
ADC Therapeutics America, Inc.
$140
ABBVIE INC.
$139
Lilly USA, LLC
$138
Puma Biotechnology, Inc.
$125
Regeneron Healthcare Solutions, Inc.
$125
Myriad Genetic Laboratories, Inc.
$118
Blueprint Medicines Corporation
$111
TESARO, Inc.
$103
Genentech USA, Inc.
$102
Seagen Inc.
$93
Janssen Biotech, Inc.
$64
Takeda Pharmaceuticals U.S.A., Inc.
$58
Celgene Corporation
$53
INTUITIVE SURGICAL, INC.
$37
Stemline Therapeutics Inc.
$35
GENZYME CORPORATION
$30
SANOFI-AVENTIS U.S. LLC
$29
Astellas Pharma US Inc
$26
Eisai Inc.
$25
Merck Sharp & Dohme LLC
$25
Bayer Healthcare Pharmaceuticals Inc.
$23
Boehringer Ingelheim Pharmaceuticals, Inc.
$18
ARRAY BIOPHARMA INC
$16
Novocure Inc.
$11
Top 3 companies account for 69.5% of total payments
Associated products mentioned in payments ›
AYVAKIT · BESREMI · BOSULIF · BRUKINSA · CREON · DARZALEX · DAURISMO · Da Vinci Surgical System · ELIQUIS · EMPLICITI · ENHERTU · ERLEADA · Enhertu · FRUZAQLA · GILOTRIF · IBRANCE · ICLUSIG · IMFINZI · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · LIBTAYO · LYNPARZA · Lenvima · MONJUVI · NERLYNX · Nerlynx · OPDIVO · Oncology · Orserdu · PADCEV · Pomalyst · PreciseTumor · REBLOZYL · RETEVMO · SKYRIZI · Stivarga · TAGRISSO · TALZENNA · TECENTRIQ · Trodelvy · VERZENIO · Vyloy · XALKORI · XTANDI · Yescarta · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (79%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $33 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
45
Per 100K population
4.8
County median income
$108,185
Nearest hospital
MEDICAL CITY DENTON
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Jain is a mixed practice specialist, with above-average Medicare volume (top 11% in TX), and high industry engagement (consulting-driven, top 17%), with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Jain experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Jain performed 24,990 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jain receive payments from pharmaceutical companies?
Yes. Dr. Jain received a total of $27,466 from 36 companies across 135 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jain's costs compare to other hematology & oncologys in Denton?
Dr. Jain's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jain) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Denton
Browse hematology & oncologys in Denton ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Kite Pharma, Inc. Payments to Doctors
See all physicians who received payments from Kite Pharma, Inc..
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Gilead Sciences, Inc. Payments to Doctors
See all physicians who received payments from Gilead Sciences, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology